Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2007
Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bock Felix, König Yanyan, Kruse Friedrich, Baier Martin, Cursiefen Claus
Аннотация
BACKGROUND: To analyze the ability of bevacizumab (Avastin) eye drops to inhibit corneal neovascularization.
DESIGN: interventional case series involving five patients (age: 42 +/- 14 years).
METHODS: Patients with aggressive corneal neovascularisation not responding to conventional therapy were treated with bevacizumab (Avastin) eye drops (5x/day; 5 mg/ml) for 0.5 to 6 months (mean: 3.6 +/- 2; four patients with limbal stem cell deficiency [three due to chemical burns and one inherited] and one after perforating keratoplasty).
RESULTS: Bevacizumab eye drops were well tolerated without obvious corneal side-effects. All five patients showed a reduction in the neovascularized area (decrease 48 +/- 28%; 13-75%).
CONCLUSIONS: Bevacizumab eye drops seem to inhibit corneal neovascularization without obvious corneal epithelial side-effects.
DESIGN: interventional case series involving five patients (age: 42 +/- 14 years).
METHODS: Patients with aggressive corneal neovascularisation not responding to conventional therapy were treated with bevacizumab (Avastin) eye drops (5x/day; 5 mg/ml) for 0.5 to 6 months (mean: 3.6 +/- 2; four patients with limbal stem cell deficiency [three due to chemical burns and one inherited] and one after perforating keratoplasty).
RESULTS: Bevacizumab eye drops were well tolerated without obvious corneal side-effects. All five patients showed a reduction in the neovascularized area (decrease 48 +/- 28%; 13-75%).
CONCLUSIONS: Bevacizumab eye drops seem to inhibit corneal neovascularization without obvious corneal epithelial side-effects.